Eribulin Mesylate Patent Expiration
Eribulin Mesylate is Used for treating patients with metastatic breast cancer. It was first introduced by Eisai Inc
Eribulin Mesylate Patents
Given below is the list of patents protecting Eribulin Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Halaven |
USRE46965 (Pediatric) | Intermediates for the preparation of analogs of Halichondrin B | Jul 08, 2027 | Eisai Inc |
| Halaven | USRE46965 | Intermediates for the preparation of analogs of Halichondrin B | Jan 08, 2027 | Eisai Inc |
| Halaven |
US6214865 (Pediatric) | Macrocyclic analogs and methods of their use and preparation |
Jan 20, 2024
(Expired) | Eisai Inc |
| Halaven | US8097648 | Methods and compositions for use in treating cancer |
Jan 22, 2021
(Expired) | Eisai Inc |
| Halaven | US6214865 | Macrocyclic analogs and methods of their use and preparation |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US6469182 | Intermediates in the preparation of macrocyclic analogs |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US7470720 | Methods and compositions for use in treating cancer |
Jun 16, 2019
(Expired) | Eisai Inc |
Eribulin Mesylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List